Richard Christian Jensen

Richard Christian Jensen

Auto-generated profile, based on publicly available information

Richard Christian Jensen

Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2018 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
HMH. David McIntyre
H. David McIntyre
DJDorte Moeller Jensen
Dorte Moeller Jensen
RJRichard C. Jensen
Richard C. Jensen
HKHenriette B. Kyhl
Henriette B. Kyhl
TJTina K. Jensen
Tina K. Jensen
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
OBJECTIVE: To define the prevalence and pregnancy outcomes related to elevated fasting venous plasma glucose (FVPG) in a Danish pregnancy cohort. RESEARCH DESIGN AND METHODS: This was an observational cohort study including 1,516 women without gestational diabetes mellitus (GDM) by Danish criteria. FVPG measured at 28 weeks’ gestation was related to pregnancy outcomes. RESULTS: With use of the World Health Organization (WHO) 2013 threshold of FVPG ≥5.1 mmol/L, 40.1% of the cohort qualified as having GDM. There was no evidence of excess fetal growth, hypertension in pregnancy, or cesarean delivery in women with FVPG <5.6 mmol/L. CONCLUSIONS: The WHO 2013 FVPG threshold for GDM is unsuitable for Denmark. It inappropriately labels as having GDM an unmanageably large number of women who are at low absolute risk of pregnancy complications.

1 July 2018 in Environment International
Verified
Journal Article
Open access
RJRichard Christian Jensen
Richard Christian Jensen
DGDorte Glintborg
Dorte Glintborg
ATAmalie Timmermann
Amalie Timmermann
FNFlemming Nielsen
Flemming Nielsen
HKHenriette Boye Kyhl
Henriette Boye Kyhl
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
Perfluoroalkyl substances (PFASs) are persistent chemicals with suspected endocrine disrupting abilities applied in consumer products. PFASs have potentially modulating effects on glucose homeostasis. Insulin resistance prevails during third trimester of pregnancy, and this challenge of glucose homeostasis may reveal putative effects of PFAS concentrations on glycemic status. To investigate associations between five serum PFASs and glucose-related outcomes in pregnant Danish women based on their risk of gestational diabetes mellitus (GDM). In the prospective Odense Child Cohort serum concentrations of five PFASs - perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA) and perfluorodecanoic acid (PFDA) - were measured at median gestational week (GW) 11 in pregnant women. An oral glucose tolerance test (OGTT) was performed at GW 28. The statistical analysis was conducted among 158 women with high GDM risk and 160 women with low GDM risk matched by gestational age. Multiple linear regression models were performed to estimate associations between PFAS concentrations and glucose, insulin, C-peptide, homeostatic model of assessment of insulin resistance (HOMA-IR) and beta cell function (HOMA-%β), and insulin sensitivity (Matsuda index) during the 2-h OGTT. In women with high risk for GDM, a two-fold increase in PFHxS concentration was significantly associated with increased fasting glucose, fasting insulin and HOMA-IR after adjusting for age, parity, educational level and pre-pregnancy BMI. Adjusting for the same confounders, a doubling in PFNA concentration was associated with higher fasting insulin and HOMA-%β. In women with low GDM risk, no associations were found between PFAS concentrations and glucose-related outcomes. PFHxS and PFNA concentrations were associated with impaired glycemic status in metabolically vulnerable pregnant women and might further enhance the risk of developing GDM.

1 July 2020 in Environmental Health Perspectives
Verified
Journal Article
Closed access
RJRichard Christian Jensen
Richard Christian Jensen
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
PLPia Veldt Larsen
Pia Veldt Larsen
DGDorte Glintborg
Dorte Glintborg
CDChristine Dalgård
Christine Dalgård
TJTina Kold Jensen
Tina Kold Jensen

1 November 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
CPCamilla Viola Buskbjerg Palm
Camilla Viola Buskbjerg Palm
DGDorte Glintborg
Dorte Glintborg
HKHenriette Boye Kyhl
Henriette Boye Kyhl
HMH. David McIntyre
H. David McIntyre
RJRichard Christian Jensen
Richard Christian Jensen
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
Insulin resistance is common in polycystic ovary syndrome (PCOS). PCOS may be associated with increased risk of gestational diabetes mellitus (GDM). To (1) review literature regarding PCOS and hyperglycaemia in pregnancy and (2) present original data from Odense Child Cohort (OCC) regarding GDM in PCOS. Literature search including original studies from 2000-18. OCC included 2548 pregnant women, 9.5% (n = 241) had PCOS. Fasting plasma glucose was measured in 1519 and 659 oral glucose tolerance tests were performed (with risk factor for GDM, n = 384, without risk factors, n = 275), applying two different GDM criteria. 30 studies were eligible using 12 different sets of diagnostic criteria for GDM. Ten studies included n > 50, control group, assessment of GDM and BMI. Results were not uniform, but supported that higher BMI, higher age, Asian ethnicity, and fertility treatment increased the risk of GDM in PCOS. In OCC, women with PCOS and controls had similar prevalences of GDM independent of different sets of criteria for GDM. PCOS may not be an individual risk factor for GDM. Pregnancies in PCOS are characterized by factors known to increase risk of GDM, especially high BMI and fertility treatment.

1 November 2020 in Environment International
Verified
Journal Article
Open access
AMAnna-Patricia Muerköster
Anna-Patricia Muerköster
HFHanne Frederiksen
Hanne Frederiksen
AJAnders Juul
Anders Juul
AAAnna-Maria Andersson
Anna-Maria Andersson
RJRichard Christian Jensen
Richard Christian Jensen
TJTina Kold Jensen
Tina Kold Jensen
Phthalates are plastic softeners with anti-androgenic properties. Prenatal exposure has led to lower testosterone (T) levels and smaller testicles in adult rats. To our knowledge, no studies have examined associations between prenatal phthalate exposure and sex hormone concentrations in infants. To study associations between phthalate exposure in Danish pregnant women and T, luteinizing hormone (LH), follicle stimulating hormone (FSH), Δ4-androstenedione (adion), 17α-hydroxyprogesterone (17-OHP) dehydroepiandrosterone sulfate (DHEAS) concentrations in their infants (N = 479) during mini-puberty. Concentrations of 12 phthalate metabolites from six phthalate diesters were measured in urine samples collected from 2010 to 2012 from 479 pregnant women participating in the Odense Child Cohort at gestational week 28 (range 20.4-30.4). Serum T, LH, FSH, adion, 17-OHP, DHEAS, weight and height were measured approximately three months after expected date of birth. Associations between prenatal phthalate exposure and gonadotropin and androgen metabolite concentrations were estimated in boys and girls separately in adjusted linear regression models. T concentration was lower in boys prenatally exposed to phthalates. Maternal urinary concentrations of summed mono-iso-butyl and mono-n-butyl phthalate (∑MBPi+n) and summed metabolites of di-iso-nonyl phthalate (∑DiNPm) were associated with lower T/LH ratio in male offspring and a dose-response association was found. FSH was 14% (95% CI: 1; 25) lower among male offspring from mothers exposed to ∑DiNPm in the highest compared to the lowest tertile. No association was found for girls. Even in these low exposed children, we found a significant decrease in T/LH ratio during mini-puberty in boys prenatally exposed to phthalates, which may suggest impairment of Leydig cells. The children will be followed as they approach adrenarche and pubarche in order to assess if long-term adverse effects persist.

27 July 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
DGDorte Glintborg
Dorte Glintborg
RJRichard Christian Jensen
Richard Christian Jensen
KBKristian Kirkelund Bentsen
Kristian Kirkelund Bentsen
ASAnne Vibeke Schmedes
Anne Vibeke Schmedes
IBIvan Brandslund
Ivan Brandslund
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
Background Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism. In pregnancy, testosterone levels may be higher in women with PCOS compared with controls. Aims To compare total testosterone (TT), free testosterone (FT), and sex hormone–binding globulin (SHBG) levels in third-trimester pregnant women with PCOS and controls and to establish reference ranges for TT, FT, and SHBG in PCOS and controls. Methods The study was part of the prospective study, Odense Child Cohort. PCOS was diagnosed by questionnaires and/or patient records. Fasting blood samples were collected at gestational week 28 and plasma TT was measured by liquid chromatography-tandem mass spectrometry in women with PCOS (n = 145) and in women without PCOS (controls, n = 1341). Results Levels of TT (mean, 2.4 vs 2.0 nmol/L) and FT (mean, 0.005 vs 0.004 nmol/L) were higher, whereas SHBG levels (mean, 447 vs 477 nmol/L) were lower in women with PCOS vs controls (all P < 0.001). Reference intervals for TT, FT, and SHBG in women with PCOS and controls were overlapping, and partitioning of reference intervals was an ambiguous decision. In multiple regression analyses, TT and FT levels were positively associated with PCOS status and BMI and inversely associated with age and parity. Offspring sex did not predict maternal TT and FT. Conclusions TT and FT levels were higher in third-trimester pregnant women with PCOS compared with controls. Separate reference interval for FT in women with PCOS should be considered.